Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV Vaccine and Tdap Co-administration in Healthy Women
NCT04071158Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2019
- Primary completion
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV) (5 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants Achieving Anti-Tetanus Toxoid Antibody Concentrations >= 0.1 IU/mL at 1 month, Percentage of Participants Achieving Anti-Diphtheria Toxoid Antibody Concentrations >= 0.1 IU/mL at 1 month and 7 more. Started Oct 2019; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04071158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04071158.